Wall Street brokerages expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to post sales of $14.56 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Amicus Therapeutics’ earnings. The lowest sales estimate is $13.63 million and the highest is $15.73 million. Amicus Therapeutics posted sales of $2.83 million in the same quarter last year, which would indicate a positive year over year growth rate of 414.5%. The firm is expected to announce its next quarterly earnings results on Wednesday, March 7th.
On average, analysts expect that Amicus Therapeutics will report full year sales of $14.56 million for the current financial year, with estimates ranging from $32.90 million to $37.13 million. For the next fiscal year, analysts forecast that the company will post sales of $0.00 per share. Zacks’ sales averages are an average based on a survey of analysts that follow Amicus Therapeutics.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The firm had revenue of $10.90 million during the quarter, compared to the consensus estimate of $9.02 million. During the same quarter in the prior year, the business posted ($0.33) EPS. The firm’s revenue for the quarter was up 419.0% on a year-over-year basis.
Shares of Amicus Therapeutics (NASDAQ FOLD) traded down $2.00 during trading on Monday, hitting $14.88. 5,667,333 shares of the stock traded hands, compared to its average volume of 3,259,764. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22. Amicus Therapeutics has a 1 year low of $5.87 and a 1 year high of $17.40. The company has a market capitalization of $2,810.00, a PE ratio of -8.13 and a beta of 1.45.
In related news, CFO William D. Baird III sold 10,000 shares of Amicus Therapeutics stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $14.72, for a total value of $147,200.00. Following the sale, the chief financial officer now owns 105,121 shares in the company, valued at $1,547,381.12. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO John F. Crowley sold 47,213 shares of Amicus Therapeutics stock in a transaction on Monday, December 4th. The shares were sold at an average price of $13.61, for a total transaction of $642,568.93. Following the completion of the sale, the chief executive officer now owns 375,214 shares in the company, valued at approximately $5,106,662.54. The disclosure for this sale can be found here. In the last quarter, insiders sold 250,390 shares of company stock worth $3,620,581. 3.40% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC lifted its position in Amicus Therapeutics by 3.4% during the third quarter. Perceptive Advisors LLC now owns 17,888,597 shares of the biopharmaceutical company’s stock valued at $269,760,000 after buying an additional 591,925 shares during the period. Redmile Group LLC lifted its position in Amicus Therapeutics by 5.9% during the second quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock valued at $121,282,000 after buying an additional 668,080 shares during the period. Jennison Associates LLC lifted its position in Amicus Therapeutics by 9.4% during the third quarter. Jennison Associates LLC now owns 9,772,025 shares of the biopharmaceutical company’s stock valued at $147,362,000 after buying an additional 838,267 shares during the period. Vanguard Group Inc. lifted its position in Amicus Therapeutics by 5.0% during the second quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock valued at $91,821,000 after buying an additional 430,486 shares during the period. Finally, Janus Henderson Group PLC lifted its position in Amicus Therapeutics by 5.8% during the third quarter. Janus Henderson Group PLC now owns 7,434,314 shares of the biopharmaceutical company’s stock valued at $112,109,000 after buying an additional 407,304 shares during the period.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.